Mixed Response of Non-Small Cell Lung Cancer Harboring the EGFR T790M Mutation to Osimertinib

被引：0
|
作者：
Shinno, Y. [1 ]
Goto, Y. [1 ]
Sato, J. [1 ]
Morita, R. [1 ]
Matsumoto, Y. [1 ]
Murakami, S. [1 ]
Kanda, S. [1 ]
Horinouchi, H. [1 ]
Fujiwara, Y. [2 ]
Yamamoto, N. [1 ]
Ohe, Y. [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
EGFR; Mixed Response; T790M;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.03-048
引用
收藏
页码：S2145 / S2145
页数：1
相关论文
共 50 条
  • [1] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
    Soejima, Kenzo
    Yasuda, Hiroyuki
    Hirano, Toshiyuki
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
  • [2] The correlation between the abundance of EGFR T790M mutation and osimertinib response in advanced non-small cell lung cancer
    Pan, Guoqiang
    Chen, Kaiyan
    Yu, Xiaoqing
    Sheng, Jiamin
    Fan, Yun
    [J]. TRANSLATIONAL CANCER RESEARCH, 2021, 10 (06) : 2895 - 2905
  • [3] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
  • [4] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
    Khozin, Sean
    Weinstock, Chana
    Blumenthal, Gideon M.
    Cheng, Joyce
    He, Kun
    Zhuang, Luning
    Zhao, Hong
    Charlab, Rosane
    Fan, Ingrid
    Keegan, Patricia
    Pazdur, Richard
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
  • [5] Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation
    Auliac, Jean Bernard
    Perol, Maurice
    Planchard, David
    Monnet, Isabelle
    Wislez, Marie
    Doubre, Helene
    Guisier, Florian
    Pichon, Eric
    Greillier, Laurent
    Mastroianni, Benedicte
    Decroisette, Chantal
    Schott, Roland
    Le Moulec, Sylvestre
    Arrondeau, Jennifer
    Cortot, Alexis B.
    Geriniere, Laurence
    Renault, Aldo
    Daniel, Catherine
    Falchero, Lionel
    Chouaid, Christos
    [J]. LUNG CANCER, 2019, 127 : 96 - 102
  • [6] Real-Life Data of Osimertinib in Pretreated Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR T790M Mutation
    Alfaro Autor, C.
    Romero, A.
    Calvo De Juan, V.
    Franco, F.
    Sanchez Romero, E.
    Ortiz Cortes, N.
    Sanz Moreno, S.
    Rodriguez Festa, A.
    Serna Blasco, R.
    Barquin Del Romo, M.
    Provencio, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S1036 - S1036
  • [7] Resistant Patterns to Osimertinib in Non-Small Cell Lung Cancer Patients with Both T790M and Sensitizing EGFR Mutation
    Lee, J. C.
    Yang, S.
    Oh, D. K.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S806 - S807
  • [8] Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation
    Miyashita, Yosuke
    Ko, Ryo
    Shimada, Naoko
    Mitsuishi, Yoichiro
    Miura, Keita
    Matsumoto, Naohisa
    Asao, Tetsuhiko
    Shukuya, Takehito
    Shibayama, Rina
    Koyama, Ryo
    Takahashi, Kazuhisa
    [J]. THORACIC CANCER, 2021, 12 (03) : 329 - 338
  • [9] Osimertinib for lung cancer cells harboring low-frequency EGFR T790M mutation
    Joshi, Asim
    Butle, Ashwin
    Hait, Supriya
    Mishra, Rohit
    Trivedi, Vaishakhi
    Thorat, Rahul
    Choughule, Anuradha
    Noronha, Vanita
    Prabhash, Kumar
    Dutt, Amit
    [J]. TRANSLATIONAL ONCOLOGY, 2022, 22
  • [10] EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
    Zheng, Qiufan
    Hong, Shaodong
    Huang, Yan
    Zhao, Hongyun
    Yang, Yunpeng
    Hou, Xue
    Zhao, Yuanyuan
    Ma, Yuxiang
    Zhou, Ting
    Zhang, Yaxiong
    Fang, Wenfeng
    Zhang, Li
    [J]. CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 9 (01):
12345